HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.76
+0.04 (+5.56%)
At close: 2:07PM EDT
Stock chart is not supported by your current browser
Previous Close0.72
Open0.00
Bid0.77 x 0
Ask0.77 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume19,138,808
Market Cap1.007B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group15 hours ago

    IIROC Trading Halt - HUGE

    VANCOUVER , Sept. 19, 2018 /CNW/ - The following issues have been halted by IIROC: Company: FSD PHARMA INC CSE Symbol: HUGE Reason: At the request of the Company Pending News Halt Time (ET): 14:07 IIROC ...

  • FSD Pharma Announces Upgraded Listing to OTCQB Venture Market
    CNW Group22 hours ago

    FSD Pharma Announces Upgraded Listing to OTCQB Venture Market

    CSE: HUGE OTCQB: FSDDF FRA: 0K9 TORONTO , Sept. 19, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (FRA: 0K9) announced today that its subordinate voting shares ...

  • Newsfile2 days ago

    Canntab Signs Collaboration and Profit Sharing Agreement with FSD Pharma for Production and Market of Oral Dose Delivery Platforms

    Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement) (OTC Pink: FSDDF) (FRA: 0K9) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma ...

  • FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica
    CNW Group7 days ago

    FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica

    CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO , Sept. 13, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that it intends to ...

  • FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History
    CNW Group8 days ago

    FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History

    CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO , Sept. 12, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9), is pleased to report that on September 11, ...

  • CNW Group9 days ago

    IIROC Trade Resumption - HUGE

    VANCOUVER , Sept. 11, 2018 /CNW/ - Trading resumes in: Company: FSD Pharma Inc. CSE Symbol: HUGE Resumption (ET): 11:00 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in ...

  • CNW Group9 days ago

    IIROC Trading Halt - HUGE

    VANCOUVER , Sept. 11, 2018 /CNW/ - The following issues have been halted by IIROC: Company: FSD Pharma Inc. CSE Symbol: HUGE Reason: Pending Company Contact / Single-Stock Circuit Breaker Halt Time (ET): ...

  • FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing
    CNW Group9 days ago

    FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing

    TORONTO, Sept. 11, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE:HUGE.CN - News) (OTC:FSDDF - News) (FRA:0K9.F - News) announces that pursuant to its Stock Option Plan, the Board approved the grant of 3,000,000 stock options for class B subordinate voting shares of the Company (the "Options") on August 14, 2018 to Dr. Raza Bokhari following his appointment as a Director. The Board has also approved an additional grant of 40,000,000 Options to Dr. Bokhari exercisable at a price of $0.74 for a period of five years.

  • ACCESSWIRE10 days ago

    3 Biotech & Marijuana Stocks to Pay Attention to this Quarter

    GTBiopharma (GTBP), for instance has been building a biopharmaceutical pipeline targeting everything from pain management to cancer treatments. This therapy targets cancer cells expressing the CD19 receptor and/or CD22 receptors, which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploys its cytotoxic diphtheria toxin payload, which inhibits protein synthesis and kills the cancer cells.

  • FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation
    CNW Group13 days ago

    FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation

    CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO , Sept. 7, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) today congratulated High Tide Ventures Inc. ...

  • FSD Pharma breaks all-time daily volume record and makes history again
    CNW Group15 days ago

    FSD Pharma breaks all-time daily volume record and makes history again

    CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO , Sept. 5, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9), is pleased to report that on September 4, ...

  • FSD Pharma Reports Q2 Results
    CNW Group20 days ago

    FSD Pharma Reports Q2 Results

    TORONTO, Aug. 30, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE:HUGE.CN - News) (OTC:FSDDF - News) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30th, 2018.   These filings are available for review on the Company's SEDAR profile at www.sedar.com. FSD Pharma continues to make Strategic early stage investments in the Cannabis industry with like minded companies that 1) provide excellent investment potential and 2) will assist FSD strategically in its business.  An example of this is evidenced by this quarters mark to market asset revaluation of FSD's holding in Cannara Biotech resulting in a $7,500,000 gain.

  • FSD Pharma reports positive pre-clinical results for proprietary CBD combination product
    CNW Group28 days ago

    FSD Pharma reports positive pre-clinical results for proprietary CBD combination product

    TORONTO, Aug. 23, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (CSE:HUGE.CN - News) (OTC:FSDDF - News) (FRA:0K9.F - News) reports today that its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann"), has achieved positive results in a pre-clinical efficacy study of its proprietary "Steady Stomach" CBD combination product for Inflammatory Bowel Disease (IBD).

  • FSD Pharma Completes Harvest and Microbial Testing of First Lot
    CNW Grouplast month

    FSD Pharma Completes Harvest and Microbial Testing of First Lot

    CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO , Aug. 21, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned ...

  • Newsfilelast month

    InvestmentPitch Media Video Discusses FSD Pharma's New Cannabis Clinical Research Collaborative Program in Israel with R&D Partner SciCann Therapeutics - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 17, 2018) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTC Pink: FSDDF) has launched a, via its strategic R&D partner, SciCann Therapeutics Inc. This comprehensive clinical research program will be executed through SciCann's strategic alliance and collaboration agreement with Mor Research Applications Ltd. - the technology transfer office and commercial arm of Clalit Healthcare Services. Clalit, Israel's largest medical insurer and healthcare provider, operates a network of ...

  • FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel
    CNW Grouplast month

    FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel

    This comprehensive clinical research program will be executed through SciCann's strategic alliance and collaboration agreement with Mor Research Applications Ltd. ("Mor") - the technology transfer office and commercial arm of Clalit Healthcare Services, Israel's largest medical insurer and healthcare provider, which operates a network of 14 full scale hospitals throughout Israel, employs over 9,000 physicians and serves the healthcare needs of over 50% of Israel's population.

  • FSD Pharma Announces Listing on Frankfurt Stock Exchange
    CNW Grouplast month

    FSD Pharma Announces Listing on Frankfurt Stock Exchange

    CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO , Aug. 14, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (OTC: FSDDF) announced today that its subordinate voting shares ...

  • FSD Pharma Inc. Announces Appointment of Dr. Raza Bokhari as New Director
    CNW Group2 months ago

    FSD Pharma Inc. Announces Appointment of Dr. Raza Bokhari as New Director

    CSE: HUGE OTC: FSDDF TORONTO , Aug. 2, 2018 /CNW/ - FSD Pharma Inc. (" FSD ") (CSE: HUGE) (OTC: FSDDF), is pleased to announce the appointment of Dr. Raza Bokhari to its Board of Directors, effective ...

  • Newsfile2 months ago

    BTV Reveals Novel Cancer Treatment, Cannabis and Lithium Companies

    Vancouver, British Columbia--(Newsfile Corp. - July 26, 2018) - On BNN Sat July 28 & Sun July 29, 2018 - BTV-Business Television goes on location with four small cap companies in popular sectors. Full EpisodeBlissCo Cannabis Corp. (CSE: BLIS) — BTV shares how this CEO's distribution background will help his company profit in the rapidly expanding cannabis market. See Feature  Critical Elements Corp. (TSXV: CRE) (OTCQX: CRECF) — Electric vehicle demand spells opportunity for the key ...

  • FSD Pharma Quebec Partner Cannara Biotech Closes Over $17.6 Million Equity Financing to Begin Build Out of First Phase of 625,000 Square Foot Indoor Grow
    CNW Group2 months ago

    FSD Pharma Quebec Partner Cannara Biotech Closes Over $17.6 Million Equity Financing to Begin Build Out of First Phase of 625,000 Square Foot Indoor Grow

    CSE:HUGE OTC:FSDDF TORONTO , July 24, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE) (OTC:FSDDF) is pleased to announce its strategic partner Cannara Biotech Inc. ...

  • FSD Pharma Appoints a Special Committee of the Board for Mergers and Acquisitions and Interim Chief Financial Officer
    CNW Group2 months ago

    FSD Pharma Appoints a Special Committee of the Board for Mergers and Acquisitions and Interim Chief Financial Officer

    TORONTO, July 23, 2018 /CNW/ - Thomas Fairfull, President and Chief Executive Officer of FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE.CN - News) (OTC:FSDDF - News), is pleased to announce the appointment of a Special Committee of the Board of Directors to focus on Merger and Acquisition Opportunities and also the appointment of Donal Carroll as interim Chief Financial Officer. A Special Committee of the Board of Directors of FSD has been formed responsible to assess Mergers and Acquisitions.

  • FSD Pharma Surpasses One Billion Shares Traded and Makes History With Annual CSE Volume Trading Record in Less Than Two Months
    CNW Group2 months ago

    FSD Pharma Surpasses One Billion Shares Traded and Makes History With Annual CSE Volume Trading Record in Less Than Two Months

    CSE: HUGE OTC: FSDDF TORONTO , June 20, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTC: FSDDF), is pleased to report that it has traded over one Billion Class ...

  • FSD Pharma Enters Into Saskatchewan Wholesale Supply MOU of up to 5,000 Kilograms With High Tide Ventures
    CNW Group2 months ago

    FSD Pharma Enters Into Saskatchewan Wholesale Supply MOU of up to 5,000 Kilograms With High Tide Ventures

    CSE:HUGE OTC:FSDDF TORONTO , July 19, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma") (CSE:HUGE) (OTC:FSDDF) today announced that its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma") ...

  • FSD Pharma Inc. announces acquisition to expand in Newfoundland for production and sales
    CNW Group2 months ago

    FSD Pharma Inc. announces acquisition to expand in Newfoundland for production and sales

    TORONTO, July 12, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE.CN - News) (OTC:FSDDF - News) is pleased to announce a binding agreement to purchase 51% of Atlantic Island Cannabis Inc. (to be renamed FSD Atlantic Pharma Inc.) effective July 4, 2018. The agreement involves a strategic investment of $40 million to drive production and sales of legal cannabis in the province of Newfoundland.

  • FSD Pharma Announces Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms
    CNW Group2 months ago

    FSD Pharma Announces Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms

    TORONTO, July 10, 2018 /CNW/ - FSD Pharma (CSE:HUGE.CN - News) (OTC:FSDDF - News) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with Canntab Therapeutics Limited (CSE:PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its 620,000 square foot facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction").